<DOC>
	<DOCNO>NCT01949051</DOCNO>
	<brief_summary>This study randomize , double blind , placebo control , 3-way cross design allergic rhinitis subject . Subjects receive repeat dose intra-nasal levocabastine 7 day period duration study 13 week . An Environmental Exposure Chamber ( EEC ) use study . The primary objective study investigate non-inferiority effect 7 day treatment levocabastine nasal symptom elicit EEC administer daily ( QD ) compare twice daily ( BID ) . Also study conducted investigate superiority effect 7 day treatment levocabastine ( QD BID ) nasal symptom elicit EEC subject compare placebo .</brief_summary>
	<brief_title>A Study Assess Intranasal Repeat Dose Effect Levocabastine Subjects With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Levocabastine</mesh_term>
	<criteria>Diagnosis Allergic Rhinitis ( AR ) , determine presence seasonal perennial rhinitis symptom several month per year , 1 year attribute infection nasal abnormality . Subjects TNSS score &gt; =6 baseline screen allergen challenge . Total nasal symptom score sum nasal congestion , rhinorrhoea , nasal itch sneeze , score scale 0 3 . Subjects positive skin prick test ( wheal &gt; =4 millimeter [ mm ] ) seasonal pollen within 12 month precede screen visit . Subjects positive radioallergosorbent test ( RAST ) ( &gt; =class 2 ) seasonal pollen within 12 month precede screen visit . There condition factor would make subject unlikely able stay chamber 4 hour . Male/females 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 19 30 kg per meter square ( m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ( definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ) ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit per milliliter ( MlU/mL ) estradiol &lt; 40 picogram ( pg ) /mL ( &lt; 147 picomol per liter [ pmol/L ] ) confirmatory ) ; childbearing potential negative pregnancy test determine urine human chorionic gonadotropin ( hCG ) test screen prior dose agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 1 week postlast dose . Capable give write informed consent , include compliance requirement restriction list consent form . Subjects nonsmoker , study define smoke &lt; 10 pack per year lifetime , smoke 6 month prior screen visit . Alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) bilirubin &lt; =1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average correct QT interval ( QTc ) value triplicate electrocardiogram ( ECGs ) obtain brief recording period : Fridericia QTc ( QTcF ) &lt; 450 millisecond ( msec ) . Nasal abnormalities likely affect outcome study , i.e . nasal septal perforation , nasal polyp , sinusitis nasal malformation . History frequent nosebleed . Subjects rhinitis medicamentosa . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Significant renal impairment , base opinion investigator , would preclude subject 's participation study . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360mL ) beer , 5 ounce ( 150mL ) wine 1.5 ounce ( 45ml ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Chronic oral steroid discontinue less 6 month prior screen . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Subjects use medication need basis , may participate study remain free medication follow period time prior screen prior dosing ( study drug ) : Nasal antihistamine : 72 hour , Oral antihistamines A ( cetirizine , fexofenadine , loratadine , desloratadine ) : 72 hour , Oral antihistamines B ( others ) : 72hours , Eye Nasal Levocasbastine : 7 day , Nasal decongestant : 24 hour , Oral decongestant : 24 hour , Nasal glucocorticosteroids : 7 day , Inhaled glucocorticoid : 1 week , Oral glucocorticosteroids : 12 week , Oral leukotriene receptor antagonist : 7 day , Oral 5lipoxygenase inhibitor : 7 day , Oral methylxanthines : 7 day Subjects recent upper respiratory tract infection ( URTIs ) allow study nasal symptom associate URTI completely resolve 3 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Allergic rhinitis</keyword>
	<keyword>levocabastine</keyword>
	<keyword>allergen challenge</keyword>
</DOC>